Literature DB >> 16641259

Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera.

Joseph J Carter1, Greg C Wipf, Margaret M Madeleine, Stephen M Schwartz, Laura A Koutsky, Denise A Galloway.   

Abstract

The variable surface loops on human papillomavirus (HPV) virions required for type-specific neutralization by human sera remain poorly defined. To determine which loops are required for neutralization, a series of hybrid virus-like particles (VLPs) were used to adsorb neutralizing activity from HPV type 16 (HPV16)-reactive human sera before being tested in an HPV16 pseudovirion neutralization assay. The hybrid VLPs used were composed of L1 sequences of either HPV16 or HPV31, on which one or two regions were replaced with homologous sequences from the other type. The regions chosen for substitution were the five known loops that form surface epitopes recognized by monoclonal antibodies and two additional variable regions between residues 400 and 450. Pretreatment of human sera, previously found to react to HPV16 VLPs in enzyme-linked immunosorbent assays, with wild-type HPV16 VLPs and hybrid VLPs that retained the neutralizing epitopes reduced or eliminated the ability of sera to inhibit pseudovirus infection in vitro. Surprisingly, substitution of a single loop often ablated the ability of VLPs to adsorb neutralizing antibodies from human sera. However, for all sera tested, multiple surface loops were found to be important for neutralizing activity. Three regions, defined by loops DE, FG, and HI, were most frequently identified as being essential for binding by neutralizing antibodies. These observations are consistent with the existence of multiple neutralizing epitopes on the HPV virion surface.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16641259      PMCID: PMC1472072          DOI: 10.1128/JVI.80.10.4664-4672.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  Chapter 15: Public health policy and cost-effectiveness analysis.

Authors:  Sue J Goldie
Journal:  J Natl Cancer Inst Monogr       Date:  2003

3.  Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers.

Authors:  Johnnie J Orozco; Joseph J Carter; Laura A Koutsky; Denise A Galloway
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Mapping of human serum-reactive epitopes in virus-like particles of human papillomavirus types 16 and 11.

Authors:  Xiaohong Wang; Zhaohui Wang; Neil D Christensen; Joakim Dillner
Journal:  Virology       Date:  2003-06-20       Impact factor: 3.616

5.  Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1.

Authors:  Joseph J Carter; Greg C Wipf; Sarah F Benki; Neil D Christensen; Denise A Galloway
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

6.  Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope.

Authors:  Jean-Rémy Sadeyen; Sylvie Tourne; Marina Shkreli; Pierre-Yves Sizaret; Pierre Coursaget
Journal:  Virology       Date:  2003-04-25       Impact factor: 3.616

7.  Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

Authors:  Diana V Pastrana; Christopher B Buck; Yuk-Ying S Pang; Cynthia D Thompson; Philip E Castle; Peter C FitzGerald; Susanne Krüger Kjaer; Douglas R Lowy; John T Schiller
Journal:  Virology       Date:  2004-04-10       Impact factor: 3.616

8.  Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students.

Authors:  Rachel L Winer; Shu-Kuang Lee; James P Hughes; Diane E Adam; Nancy B Kiviat; Laura A Koutsky
Journal:  Am J Epidemiol       Date:  2003-02-01       Impact factor: 4.897

Review 9.  Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality.

Authors:  F Xavier Bosch; Silvia de Sanjosé
Journal:  J Natl Cancer Inst Monogr       Date:  2003

10.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

Authors:  Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins; Anne Schuind; Toufik Zahaf; Bruce Innis; Paulo Naud; Newton S De Carvalho; Cecilia M Roteli-Martins; Julio Teixeira; Mark M Blatter; Abner P Korn; Wim Quint; Gary Dubin
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321

View more
  25 in total

Review 1.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.

Authors:  Timothy D Culp; Christin M Spatz; Cynthia A Reed; Neil D Christensen
Journal:  Virology       Date:  2007-01-12       Impact factor: 3.616

3.  Multiscale simulation of microbe structure and dynamics.

Authors:  Harshad Joshi; Abhishek Singharoy; Yuriy V Sereda; Srinath C Cheluvaraja; Peter J Ortoleva
Journal:  Prog Biophys Mol Biol       Date:  2011-07-23       Impact factor: 3.667

Review 4.  Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types.

Authors:  Christine Roberts; Tina Green; Erica Hess; Katie Matys; Martha J Brown; Richard M Haupt; Alain Luxembourg; Scott Vuocolo; Alfred Saah; Joseph Antonello
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.

Authors:  Sara L Bissett; Anna Godi; Maxime J J Fleury; Antoine Touze; Clementina Cocuzza; Simon Beddows
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

6.  Genetic variability of human papillomavirus type 66 L1 gene among women presenting for cervical cancer screening in Chile.

Authors:  Monserrat Balanda; Jorge Fernández; Nicolás Vergara; Constanza Campano; Loredana Arata; Héctor San Martín; Eugenio Ramírez
Journal:  Med Microbiol Immunol       Date:  2019-06-04       Impact factor: 3.402

7.  Human Papillomavirus Major Capsid Protein L1 Remains Associated with the Incoming Viral Genome throughout the Entry Process.

Authors:  Stephen DiGiuseppe; Malgorzata Bienkowska-Haba; Lucile G M Guion; Timothy R Keiffer; Martin Sapp
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

8.  The use of human papillomavirus seroepidemiology to inform vaccine policy.

Authors:  Mark Schiffman; Mahboobeh Safaeian; Nicolas Wentzensen
Journal:  Sex Transm Dis       Date:  2009-11       Impact factor: 2.830

Review 9.  Understanding and learning from the success of prophylactic human papillomavirus vaccines.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Nat Rev Microbiol       Date:  2012-09-10       Impact factor: 60.633

10.  Specificity of L1 peptides versus virus-like particles for detection of human papillomavirus-positive cervical lesions in females attending Engativa Hospital, Bogota, Colombia.

Authors:  Mauricio Urquiza; Ricardo Sánchez; Jairo Amaya; Sandra León; Jenny Acosta; Manuel A Patarroyo; Milena Camargo; Manuel E Patarroyo
Journal:  J Clin Microbiol       Date:  2008-09-17       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.